Answers are grounded in this paper and cite their sources.
Recombinant alpha-galactosidase A replacement therapy cleared microvascular endothelial deposits of globotriaosylceramide from the kidneys, heart, and skin in patients with Fabry's disease, reversing the pathogenesis of the chief clinical manifestations of this disease.
No takes yet. Share an insight, caveat, or question.
Eng et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: